SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 95 400 KRW -2.25% Market Closed
Market Cap: 7.5T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SK Biopharmaceuticals Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Net Income (Common)
-â‚©32.9B
CAGR 3-Years
49%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Net Income (Common)
â‚©165.3B
CAGR 3-Years
12%
CAGR 5-Years
31%
CAGR 10-Years
6%
Hanmi Science Co Ltd
KRX:008930
Net Income (Common)
â‚©105B
CAGR 3-Years
25%
CAGR 5-Years
45%
CAGR 10-Years
17%
Hanmi Pharm Co Ltd
KRX:128940
Net Income (Common)
â‚©184.4B
CAGR 3-Years
100%
CAGR 5-Years
40%
CAGR 10-Years
15%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Net Income (Common)
â‚©5.1B
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
-6%
C
Celltrion Pharm Inc
KOSDAQ:068760
Net Income (Common)
â‚©16.5B
CAGR 3-Years
-26%
CAGR 5-Years
81%
CAGR 10-Years
16%
No Stocks Found

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
7.5T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co Ltd., a prominent player in the global biopharmaceutical landscape, has carved out a niche in the development of innovative therapies for central nervous system (CNS) disorders. Founded in South Korea as a subsidiary of the SK Group, the company has swiftly gained recognition for its commitment to research and development, particularly in the realm of epilepsy treatments. Its flagship product, Cenobamate, has received approvals in various international markets, establishing a substantial revenue stream and bolstering SK Biopharmaceuticals’ reputation for tackling complex neurological conditions. This focus on underserved medical needs not only highlights the company’s scientific prowess but also reflects its strategic positioning within a growing market projected to expand significantly in the coming years. For investors, SK Biopharmaceuticals embodies a blend of growth potential and stability, driven by a robust pipeline of both established and novel therapies. The company is leveraging cutting-edge technology and extensive clinical research to explore additional indications for its existing products while continuing to develop new candidates. With a strong financial foundation and increasing market penetration, SK Biopharmaceuticals is poised to capitalize on the surging demand for innovative CNS treatments. As the company continues to expand its footprint globally, its commitment to quality, patient-centric approaches, and strategic partnerships will likely enhance shareholder value, making it an attractive consideration for those looking to invest in the biopharmaceutical sector.

Intrinsic Value
42 162.19 KRW
Overvaluation 56%
Intrinsic Value
Price

See Also

What is SK Biopharmaceuticals Co Ltd's Net Income (Common)?
Net Income (Common)
-32.9B KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Net Income (Common) amounts to -32.9B KRW.

What is SK Biopharmaceuticals Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
25%

Over the last year, the Net Income (Common) growth was 76%. The average annual Net Income (Common) growth rates for SK Biopharmaceuticals Co Ltd have been 49% over the past three years , 25% over the past five years .

Back to Top